Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > TH1902 effects on Progranulin

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Apr 04, 2021 2:42pm

89 Views

Post# 32935245

RE:RE:RE:TH1902 effects on Progranulin

TH1902 doesn't have to competitively inhibit progranulin from binding to Sortilin. It kills the cells that have Sortilin leaving nothing for progranulin to bind to.

jfm1330 wrote: The competitive effect of TH1902 on sortilin receptors, versus progranulin is too short in my view to have any meaningful effect on cancer proliferation.

Wino115 wrote: I think you've stumbled upon one of the possible methods of action that both Spartrap and Qwerty are hoping is one of the 3 MOAs for TH1902. It may also be part of the disruption of vascular mimicry that they have seen in vitro. That is one of the more intriguing possibilities of the peptide and whole platform. If they can uncover that it does work beneficially in three different ways, it's not just a home run, it's a grand slam....or for our hockey-heads, a hat-trick!

jeffm34 wrote: If Th1902 can target and kill cancer cells that have Sortilin, it should also have positive effects on cancer progression by inhibiting Progranulin.

"Progranulin is involved in biological processes such as wound healing, inflammation and cancer progression. Progranulin and its receptor sortilin are known to be highly expressed in subgroups of breast cancer and are further associated with a clinically aggressive phenotype."